BC Innovations | Apr 18, 2017
Distillery Therapeutics


INDICATION: Stroke Mouse studies suggest promoting MSR-1 expression could help treat ischemic stroke. MSR-1 levels were higher in brain-derived myeloid cells from a mouse model of ischemic stroke than cells from normal mice. In the...
BC Innovations | Feb 4, 2016
Translation in Brief

Immunotherapy gets cerebral

Amid a growing debate about how large a role the peripheral immune system plays in Alzheimer's disease (AD), and whether its effects are harmful or helpful, a team at the Weizmann Institute of Science has...
BC Innovations | Mar 5, 2015
Distillery Therapeutics

Therapeutics: CD36 (GPIV); macrophage scavenger receptor 1 (MSR-1; SR-A; CD204)

Cardiovascular disease INDICATION: Atherosclerosis In vitro and mouse studies suggest sugar-based amphiphilic nanoparticles could help treat atherosclerosis. Macrophage recruitment and oxidized low-density lipoprotein (LDL) uptake via scavenger receptors such as CD36 and MSR-1 contributes to...
BC Innovations | Jul 29, 2010
Cover Story

Triglyceride trouble from tumors

A team led by researchers at the University of South Florida has found that cancer cells alter both the amount and the type of lipid in dendritic cells, decreasing their ability to initiate immunity. The...
BioCentury | Oct 19, 2009

A Very Long Walk

Last week's positive vote by an FDA advisory committee on Acorda Therapeutics Inc. 's Fampridine-SR validated the company's work with multiple sclerosis patient groups early in clinical development to identify improved walking ability as a...
BC Extra | Jun 5, 2009
Financial News

Xanodyne raises $38M, names Valentino CEO

Xanodyne Pharmaceuticals Inc. (Newport, Ky.) raised $38 million in a private round led by MPM Capital. AIG Investments; Aisling Capital; Blue Chip Venture; Essex Woodlands; HealthCare Ventures; and Union Springs also participated. All are existing...
BC Innovations | Apr 16, 2009
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Macrophage scavenger receptor 1 (MSR1; SR-A; CD204); toll-like receptor 4 (TLR4) Studies in mice and in cell culture suggest that...
BioCentury | Mar 2, 2009

Ebb & Flow

If LPs like to see results before investing their money, Sofinnova 's chances of hitting the target for its Sofinnova Capital VI fund were boosted last week when the French VC sold medical device company...
BioCentury | Nov 3, 2008

Ebb & Flow

Cardiovascular and pulmonary company Dyax (NASDAQ: DYAX) has found a bevy of ways to bring in cash this year, despite the poor funding environment. Its latest move was to set up a $50 million committed...
BC Extra | Oct 28, 2008
Financial News

Xanodyne pulls IPO

Pain and women's health company Xanodyne (Newport, Ky.) withdrew its IPO, citing market conditions. Last year, the company filed to raise up to $86.3 million in an offering underwritten by Morgan Stanley; Deutsche Bank; RBC...
Items per page:
1 - 10 of 21